Article Information
History
- December 22, 2021.
Article Versions
- You are currently viewing Version 1 of this article (December 22, 2021 - 19:14).
- Version 2 (January 3, 2022 - 19:14).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Benjamin G. Bitler1,
- Tomomi M. Yamamoto1,
- Alexandra McMellen2,
- Hyunmin Kim3 and
- Zachary L. Watson1,#
- 1Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO 80045, USA
- 2Cancer Biology Graduate Program, University of Colorado, Aurora, CO 80045, USA
- 3Translational Bioinformatics and Cancer Systems Biology Laboratory, Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
- ↵#Corresponding Author: Zachary L. Watson, PhD, Division of Reproductive Sciences, Department of Obstetrics and Gynecology, 12700 E. 19th Ave, MS 8613, Aurora, CO 80045, Phone: 303-724-8682, Fax: 303-724-3512, zachary.watson{at}cuanschutz.edu
Posted December 22, 2021.
BRPF3 knockdown or inhibition moderately reverses olaparib resistance in high grade serous ovarian carcinoma, but depletion of H3K14 acetylation has no effect
